Spero Therapeutics Inc (SPRO) Stock Price, Quote & News

Company Profile

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 242 1600

Website: sperotherapeutics.com

Address:

675 Massachusetts Avenue, 14th Floor, Cambridge, United States

zerodayrounder May. 13 at 6:08 PM

$SPRO my guess is SPRO board wants to get one last equity award for the June cycle and hand off SPRO cash shell to reverse merger target in the September time frame. Hopefully that means SPRO gets the ball rolling on tebi asset sale today at least as it seems there is a gating factor here re 30 day HSR review; June 18 PDUFA and June 23 SPRO AGM. I would think shareholders would need to know of the tebi asset sale completed an HSR review (and FDA approved) before authorizing 120 million new shares. Seems like timing is becoming a tenuous situation for all involved.

3 · Reply

zerodayrounder May. 13 at 12:58 AM

File under: interesting $SPRO $GSK Immunitas platform validated? IMT-009 not a lead asset and not really related to GSK core areas of anti infectives and oncology Boehringer makes €407M bet on Immunitas’ inflammatory asset https://www.fiercebiotech.com/biotech/boehringer-furthers-inflammatory-expansion-eu407m-biobuck-bet-immunitas-asset

1 · Reply

DDel May. 12 at 6:28 PM

$SPRO $GSK

0 · Reply

zerodayrounder May. 12 at 4:35 PM

At least Ryan Cohen $GME actually disclosed what they planned to use 2.5 billion extra shares on $EBAY $SPRO has got some 'splainin to do for the 120 million extra authorized shares they are requesting on June 23. 30-day HSR from May 15 gives about a week separation from June 23 AGM ... IF ... the share authorization is tied to a tebi asset sale. https://www.bamsec.com/filing/119312526217168?cik=1326380

0 · Reply

zerodayrounder May. 12 at 12:18 AM

$SPRO $GSK

0 · Reply

zerodayrounder May. 11 at 7:44 PM

$SPRO following $GSK lower. Maybe similar to the GSK move that began on Jan 15 and was final flush before RAPT and a move higher into Q4 report.

0 · Reply

CharlieeMungerTWITS May. 11 at 9:59 AM

$SPRO “No leaks” arguments cut both ways. Real M&A often leaks through unusual options activity, abnormal volume, bankers/law firms entering, etc.

0 · Reply

zerodayrounder May. 11 at 3:14 AM

$SPRO $GSK one last thing, if GSK buys tebi it starts the 30 day HSR review this week and would conclude around June 15. The PDUFA is June 18. And the SPRO AGM is June 23. Also, if these hypothetical transactions (Tebi asset sale + reverse merger) were to be announced -- tomorrow -- they would be massively material subsequent events that would require significant footnotes in the 10Q that is due by May 15. I wonder if SPRO pushed back the Q1 report til Wednesday to give the accounting team and PwC auditors a little extra time to sign off on subsequent event disclosures. Waiting til May 18 is pushing the timelines super duper close IF these ideas are anywhere near reality. You also risk leaks if lots of parties are in the know on these transactions including auditors, lawyers, advisors, insiders etc etc

0 · Reply

zerodayrounder May. 10 at 2:29 PM

$SPRO $GSK

1 · Reply

zerodayrounder May. 9 at 6:42 PM

$SPRO $GSK hopefully the Barney's and the Limey's are working this weekend https://www.youtube.com/watch?v=gArnm_Uicsw

0 · Reply

Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

Mar 26, 2026, 4:05 PM EDT - 6 weeks ago

Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update

Mar 18, 2026, 4:05 PM EDT - 7 weeks ago

Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026

2025-12-19T13:17:06.000Z - 5 months ago

Spero announces GSK filed NDA resubmission to FDA for tebipenem HBr

GSK

Dec 19, 2025, 8:00 AM EST - 5 months ago

Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis

2025-11-28T13:10:22.000Z - 5 months ago

Spero Therapeutics announces inducement grant under Nasdaq listing rule

Nov 28, 2025, 8:00 AM EST - 5 months ago

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 13, 2025, 4:05 PM EST - 6 months ago

Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update

Nov 4, 2025, 4:05 PM EST - 6 months ago

Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025

2025-10-21T09:50:26.000Z - 7 months ago

Spero Therapeutics, GSK announce PIVOT-PO trial efficacy and safety results

GSK

Oct 21, 2025, 2:00 AM EDT - 7 months ago

PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

Oct 14, 2025, 8:00 AM EDT - 7 months ago

Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek

Aug 12, 2025, 4:30 PM EDT - 9 months ago

Spero Therapeutics Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:01 PM EDT - 9 months ago

Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

Aug 5, 2025, 4:05 PM EDT - 10 months ago

Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025

2025-05-28T20:13:00.000Z - 1 year ago

Spero Therapeutics Stock (SPRO) Rockets 225% on Clinical Trial Data

GSK

2025-05-28T11:20:29.000Z - 1 year ago

GSK reports PIVOT-PO study for tebipenem HBr stopped early for efficacy

GSK

2025-05-28T11:11:24.000Z - 1 year ago

Spero Therapeutics, GSK announce Phase 3 PIVOT-PO trial met primary endpoint

GSK

May 28, 2025, 7:00 AM EDT - 1 year ago

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

GSK

May 13, 2025, 4:01 PM EDT - 1 year ago

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

May 5, 2025, 8:00 AM EDT - 1 year ago

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

2025-04-28T20:11:11.000Z - 1 year ago

Spero Therapeutics appoints Esther Rajavelu will serve as CEO

Apr 28, 2025, 4:01 PM EDT - 1 year ago

Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Spero Therapeutics Earnings Call Transcript: Q4 2024

2025-03-27T20:20:55.000Z - 1 year ago

Spero Therapeutics reports Q4 EPS (38c), consensus (31c)

Mar 27, 2025, 4:01 PM EDT - 1 year ago

Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

Mar 4, 2025, 3:10 PM EST - 1 year ago

Spero Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 25, 2025, 10:15 AM EST - 1 year ago

UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 7:00 AM EST - 1 year ago

Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

2025-01-10T12:31:40.000Z - 1 year ago

Spero Therapeutics announces interim leadership changes

Jan 10, 2025, 7:00 AM EST - 1 year ago

Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

2024-12-20T11:16:22.000Z - 1 year ago

Spero Therapeutics downgraded at Evercore on lack of capital allocation clarity

2024-12-20T10:45:23.000Z - 1 year ago

Spero Therapeutics downgraded to In Line from Outperform at Evercore ISI

2024-11-18T12:41:28.000Z - 1 year ago

Spero Therapeutics downgraded to Hold from Buy at TD Cowen

2024-11-14T21:20:42.000Z - 1 year ago

Spero Therapeutics reports Q3 EPS (32c), consensus (36c)

Nov 14, 2024, 4:05 PM EST - 1 year ago

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

2024-11-04T11:10:15.000Z - 1 year ago

Spero Therapeutics price target lowered to $5 from $7 at H.C. Wainwright

Oct 16, 2024, 4:05 PM EDT - 1 year ago

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024

Oct 2, 2024, 4:30 PM EDT - 1 year ago

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

Sep 17, 2024, 1:20 PM EDT - 1 year ago

Spero Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2024, 4:00 PM EDT - 1 year ago

Spero Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 5, 2024, 4:30 PM EDT - 1 year ago

Spero Therapeutics Earnings Call Transcript: Q2 2024

Aug 5, 2024, 4:01 PM EDT - 1 year ago

Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update

Jul 29, 2024, 4:05 PM EDT - 1 year ago

Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024

May 20, 2024, 1:30 PM EDT - 2 years ago

Spero Therapeutics Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 16, 2024, 4:05 PM EDT - 2 years ago

Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

May 15, 2024, 4:05 PM EDT - 2 years ago

Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update

May 8, 2024, 8:00 AM EDT - 2 years ago

Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024

May 1, 2024, 4:07 PM EDT - 2 years ago

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 13, 2024, 4:30 PM EDT - 2 years ago

Spero Therapeutics Earnings Call Transcript: Q4 2023

Mar 13, 2024, 4:01 PM EDT - 2 years ago

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

Mar 6, 2024, 8:05 AM EST - 2 years ago

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024

Mar 4, 2024, 9:50 AM EST - 2 years ago

Spero Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 28, 2024, 8:05 AM EST - 2 years ago

Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

Feb 26, 2024, 8:05 AM EST - 2 years ago

Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference

Jan 5, 2024, 8:05 AM EST - 2 years ago

Spero Therapeutics Provides Corporate Update and 2024 Outlook

Jan 2, 2024, 8:05 AM EST - 2 years ago

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Nov 28, 2023, 7:55 AM EST - 2 years ago

Spero Therapeutics Transcript: 6th Annual Evercore ISI HealthCONx Conference

Nov 13, 2023, 4:30 PM EST - 2 years ago

Spero Therapeutics Earnings Call Transcript: Q3 2023

Nov 6, 2023, 8:05 AM EST - 2 years ago

Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Nov 1, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

Sep 20, 2023, 4:05 PM EDT - 2 years ago

Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor Conference

Sep 6, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 10, 2023, 4:30 PM EDT - 2 years ago

Spero Therapeutics Earnings Call Transcript: Q2 2023

Aug 3, 2023, 8:05 AM EDT - 3 years ago

Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

Jul 31, 2023, 8:05 AM EDT - 3 years ago

Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr

Jun 14, 2023, 8:05 AM EDT - 3 years ago

Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer

May 11, 2023, 4:30 PM EDT - 3 years ago

Spero Therapeutics Earnings Call Transcript: Q1 2023

May 11, 2023, 4:05 PM EDT - 3 years ago

Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business Update

May 4, 2023, 8:05 AM EDT - 3 years ago

Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

Apr 26, 2023, 8:05 AM EDT - 3 years ago

Spero Therapeutics to Present at Upcoming Investor Conference

Apr 14, 2023, 8:05 AM EDT - 3 years ago

Spero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases

Mar 30, 2023, 4:05 PM EDT - 3 years ago

Spero Therapeutics Announces Fourth Quarter and Full Year 2022 Operating Results and Provides Business Update

Mar 30, 2023, 3:30 PM EDT - 3 years ago

Spero Therapeutics Earnings Call Transcript: Q4 2022

Mar 13, 2023, 8:05 AM EDT - 3 years ago

Spero Therapeutics Reschedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call to March 30, 2023

zerodayrounder May. 13 at 6:08 PM

3 · Reply

zerodayrounder May. 13 at 12:58 AM

1 · Reply

DDel May. 12 at 6:28 PM

$SPRO $GSK

0 · Reply

zerodayrounder May. 12 at 4:35 PM

0 · Reply

zerodayrounder May. 12 at 12:18 AM

$SPRO $GSK

0 · Reply

zerodayrounder May. 11 at 7:44 PM

$SPRO following $GSK lower. Maybe similar to the GSK move that began on Jan 15 and was final flush before RAPT and a move higher into Q4 report.

0 · Reply

CharlieeMungerTWITS May. 11 at 9:59 AM

$SPRO “No leaks” arguments cut both ways. Real M&A often leaks through unusual options activity, abnormal volume, bankers/law firms entering, etc.

0 · Reply

zerodayrounder May. 11 at 3:14 AM

0 · Reply

zerodayrounder May. 10 at 2:29 PM

$SPRO $GSK

1 · Reply

zerodayrounder May. 9 at 6:42 PM

$SPRO $GSK hopefully the Barney's and the Limey's are working this weekend https://www.youtube.com/watch?v=gArnm_Uicsw

0 · Reply

zerodayrounder May. 9 at 12:26 AM

$GSK frenemy Shionogi (ViiV Healthcare JV partner; AMR challenger) reports on Tuesday in Japan. Shionogi rumored to be the buyer of $ITRM Orlynvah out of the liquidation proceedings (according to that group of internet sleuths). Perhaps GSK wants to front-run Shionogi by announcing acquisition of tebipenem rights and the reverse merger Tx's considered ad nauseum on my stream to set the narrative for oral carbapenems for cUTI as #1 player in AMR (as the GSK Chairman discussed at the AGM) while funding another shot on goal in oncology space. $SPRO Q1 earnings just becoms a date to report Q1 numbers and file 10-Q with the fireworks happening on Monday?

2 · Reply

Homepayment May. 8 at 7:33 PM

$SPRO

0 · Reply

zerodayrounder May. 8 at 6:06 PM

$SPRO it is only obvious, when it becomes obviously obvious "Allegedly"

0 · Reply

zerodayrounder May. 8 at 5:49 PM

$SPRO was trading about 250k per session in the 8-9 days leading up to March 26, 2026 Q4 report in a downtrend. We are doing about 500k avg over the last week or so and trying to turn up just over 9EMA and 50SMA. I don't think any accumulation has to do with a PDUFA date. The market would still look at SPRO as a royalty shell with uncertain cash flows and no control over its own destiny at all (along with GSK overhang/control). And high likelihood of misallocating royalty cash flows in a drug pipeline it has no experience or team set up to manage. The only solution is for GSK to back up its Chairman's claims about being #1 in AMR and acquiring full rights of tebipenem, then effecting a reverse merge into a promising Boston area biotech w/ great pipeline, team and a need for $$$ to fund Phase 2/3 clinical trials that GSK wants to invest in with its 16% SPRO equity. NewCO takes over SPRO nasdaq listing, brings in new management and replaces entire SPRO board. It is written.

1 · Reply

Inc82 May. 8 at 5:22 PM

$SPRO accumulation?

0 · Reply

zerodayrounder May. 8 at 2:37 PM

$SPRO $GSK "let me tell you somethin', ya suspect, yeah you." 🫵 https://www.youtube.com/watch?v=OHSYWIAAY2o

0 · Reply

MorganHoratio May. 8 at 1:51 PM

Google just released its updated 13F filing which shows all the stocks it owned as of the end of Q1: $SPRO - 889,979 $TEM - 1,551,102 $TNYA - 915,705 $PATH - 7,034,337 $VERA - 241,264 Google’s Q1 13F is a definitive bet on Agentic AI and Data-Driven Healthcare! The 7M+ share stake in $PATH (UiPath) is a massive signal—as 2026 marks the rise of AI Agents, Google is weaponizing UiPath to bridge the gap between Gemini’s logic and enterprise execution. Meanwhile, $TEM (Tempus AI) just validated Google's thesis with a stellar Q1 beat, posting 36% revenue growth. Do you think Google’s $PATH position is the key to countering Microsoft’s automation dominance? Which play has more "moonshot" potential for the rest of 2026: the automation of $PATH or the precision of $TEM?

2 · Reply

zerodayrounder May. 7 at 9:40 PM

a trip down memory lane "The Miracle of Science" wish I could transport back to 2007 $SPRO

0 · Reply

Clem4863 May. 7 at 8:08 PM

$SPRO this is an interesting one to monitor. High risk (Rejection, Dilution) / High Reward (Approval, Acquisition)

1 · Reply

zerodayrounder May. 7 at 3:03 PM

$SPRO "allegedly"

0 · Reply

zerodayrounder May. 7 at 1:56 PM

$GSK chairman spends about 5 sentences on anti-microbial resistance focus/market leadership in his short opening statement. And pipeline execution, exceeding 2031 targets and accelerating R&D. Tebipenem for cUTI!! $2.7B peak annual sales by 2031 (saving $200 mln/yr in royalties by then) lets go! $SPRO

1 · Reply

Homepayment May. 7 at 4:31 AM

$SPRO I see a lot of speculation here, but it appears to me they’re gonna sell, issue more shares, hit the ATM and start whatever venture that have planned that they’re not discussing with 1.5-2B. Tell me I’m wrong for debate and conversation purposes. I’d like to understand WTF is going on at this point, seems there are about 5 or 6 different theories..

0 · Reply

Market Cap	147.65M
Revenue (ttm)	66.80M
Net Income (ttm)	8.57M
EPS (ttm)	N/A
PE Ratio	21.33
Forward PE	N/A
Profit Margin	12.83%
Debt to Equity Ratio	0.00

Volume	454,286
Avg Vol	406,596
Day's Range	N/A - N/A
Shares Out	57.90M
Stochastic %K	50%
Beta	1.43
Analysts	Sell
Price Target	$4.50